<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vitamin E supplementation in people with cystic fibrosis - Okebukola, PO - 2020 | Cochrane Library</title> <meta content="Vitamin E supplementation in people with cystic fibrosis - Okebukola, PO - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009422.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vitamin E supplementation in people with cystic fibrosis - Okebukola, PO - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009422.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009422.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Vitamin E supplementation in people with cystic fibrosis" name="citation_title"/> <meta content="Peter O Okebukola" name="citation_author"/> <meta content="Johns Hopkins Bloomberg School of Public Health" name="citation_author_institution"/> <meta content="ookebuko@jhsph.edu" name="citation_author_email"/> <meta content="Sonal Kansra" name="citation_author"/> <meta content="Sheffield Children's Hospital NHS Trust" name="citation_author_institution"/> <meta content="Joanne Barrett" name="citation_author"/> <meta content="University Hospitals Birmingham NHS Foundation Trust" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD009422.pub4" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/09/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009422.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009422.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009422.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="alpha-Tocopherol [administration &amp; dosage]; Bias; Cystic Fibrosis [*blood]; *Dietary Supplements; Exocrine Pancreatic Insufficiency [complications]; Placebos [administration &amp; dosage]; Randomized Controlled Trials as Topic; Vitamin E [*administration &amp; dosage, blood, chemistry]; Vitamin E Deficiency [prevention &amp; control]; Vitamins [*administration &amp; dosage, chemistry]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009422.pub4&amp;doi=10.1002/14651858.CD009422.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009422\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009422\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009422\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009422\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ko","ms","ja","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009422.pub4",title:"Vitamin E supplementation in people with cystic fibrosis",firstPublishedDate:"Sep 6, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009422.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009422.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009422.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009422.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009422.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009422.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009422.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009422.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009422.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009422.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2819 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009422.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/full#CD009422-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/full#CD009422-sec-0087"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/full#CD009422-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/full#CD009422-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/full#CD009422-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/full#CD009422-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/full#CD009422-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/full#CD009422-sec-0079"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/appendices#CD009422-sec-0092"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/supinfo/CD009422StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/supinfo/CD009422StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vitamin E supplementation in people with cystic fibrosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/information#CD009422-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Peter O Okebukola</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/information#CD009422-cr-0005">Sonal Kansra</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009422.pub4/information#CD009422-cr-0006">Joanne Barrett</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/information/en#CD009422-sec-0098">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 September 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009422.pub4">https://doi.org/10.1002/14651858.CD009422.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009422-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009422-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009422-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009422-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009422-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009422-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009422-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009422-abs-0001" lang="en"> <section id="CD009422-sec-0001"> <h3 class="title" id="CD009422-sec-0001">Background</h3> <p>People with cystic fibrosis are at an increased risk of fat‐soluble vitamin deficiency, including vitamin E. Vitamin E deficiency can cause a host of conditions such as haemolytic anaemia, cerebellar ataxia and cognitive difficulties. Vitamin E supplementation is widely recommended for people with cystic fibrosis and aims to ameliorate this deficiency. This is an updated version of the review. </p> </section> <section id="CD009422-sec-0002"> <h3 class="title" id="CD009422-sec-0002">Objectives</h3> <p>To determine the effects of any level of vitamin E supplementation on the frequency of vitamin E deficiency disorders in people with cystic fibrosis. </p> </section> <section id="CD009422-sec-0003"> <h3 class="title" id="CD009422-sec-0003">Search methods</h3> <p>We searched the Cochrane Group's Cystic Fibrosis Trials Register and also searched international online trial registries for any ongoing clinical trials that were not identified during our register search. </p> <p>Date of last search of the Register: 11 August 2020.<br/>Date of last search of international online trial registries: 20 July 2020. </p> </section> <section id="CD009422-sec-0004"> <h3 class="title" id="CD009422-sec-0004">Selection criteria</h3> <p>Randomised controlled trials and quasi‐randomised controlled trials comparing any preparation of vitamin E supplementation to placebo or no supplement, regardless of dosage or duration. </p> </section> <section id="CD009422-sec-0005"> <h3 class="title" id="CD009422-sec-0005">Data collection and analysis</h3> <p>Two authors extracted outcome data from each study (published information) and assessed the risk of bias of each included study. They assessed the quality of the evidence using GRADE. </p> </section> <section id="CD009422-sec-0006"> <h3 class="title" id="CD009422-sec-0006">Main results</h3> <p>Four studies with a total of 141 participants were included in the review, two of these were in children (aged six months to 14.5 years), and two did not specify participants’ age. All studies used different formulations and doses of vitamin E for various durations of treatment (10 days to six months). Two studies compared the supplementation of fat‐soluble as well as water‐soluble formulations to no supplementation in different arms of the same study. A third study compared a water‐soluble formulation to a placebo; and in the fourth study a fat‐soluble formulation of vitamin E was assessed against placebo. </p> <p>There was limited detail about randomisation and blinding in the included studies which compromises the quality of the evidence base for the review. The heterogeneous mix of the formulations with differing biovailabilities among these studies also limits the generalisability of the data to the wider cystic fibrosis population. </p> <p>None of the studies in either comparison report the review's primary outcomes of vitamin E total lipid ratio or the incidence of vitamin E‐specific deficiency disorders, or the secondary outcomes lung function or quality of life. </p> <p><b>Water‐soluble vitamin E</b> </p> <p>Water‐soluble vitamin E may improve serum vitamin E levels compared with control at six months, one study (45 participants), mean difference (MD) 19.74 umol/L (95% confidence interval (CI) 13.48 to 26.00) (low‐quality evidence). Similar results were also seen at one month, two studies (32 participants), MD 17.66 umol/L (95% CI 10.59 to 24.74) and at three months, one study (45 participants), MD 11.61 umol/L (95% CI 4.77 to 18.45). Only one study (45 participants) reported weight (secondary outcome of growth and nutritional status) at one and six months, but showed no difference between treatment and control at either time point. </p> <p><b>Fat‐soluble vitamin E</b> </p> <p>Two studies (36 participants) reported higher levels of serum vitamin E at one month with fat‐soluble vitamin E compared with control, MD 13.59 umol/L (95% CI 9.52 to 17.66); however, at three months one study (36 participants) showed no difference between treatment and control. No studies in this comparison reported on growth or nutritional status. </p> </section> <section id="CD009422-sec-0007"> <h3 class="title" id="CD009422-sec-0007">Authors' conclusions</h3> <p>Vitamin E supplementation may lead to an improvement in vitamin E levels in people with cystic fibrosis, although evidence we assessed was low quality. No data on other outcomes of interest were available to allow conclusions about any other benefits of this therapy. </p> <p>In future, larger studies are needed, especially in people already being treated with enteric‐coated pancreatic enzymes and supplemented with vitamin E, to look at more specific outcome measures such as vitamin E status, lung function and nutritional status. Future studies could also look at the optimal dose of vitamin E required to achieve maximal clinical effectiveness. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009422-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009422-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009422-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009422-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009422-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD009422-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009422-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009422-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD009422-abs-0015">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009422-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009422-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009422-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009422-abs-0002" lang="en"> <h3>Vitamin E supplementation in people with cystic fibrosis</h3> <p><b>Review question</b> </p> <p>We wanted to know what effects, if any, vitamin E supplementation (at any dose) has on how often people with cystic fibrosis have health problems due to vitamin E deficiency. </p> <p><b>Background</b> </p> <p>Approximately 85% to 90% of people with cystic fibrosis do not produce enough enzymes in their pancreas and are not able to absorb fat when digesting food; they are also likely to have problems absorbing the fat‐soluble vitamins A, D, E and K. If levels of vitamin E are too low, this may cause blood disorders and problems with the nervous system, with memory and with thinking skills. </p> <p><b>Search date</b> </p> <p>We last searched for evidence on 20 July 2020.</p> <p><b>Study characteristics</b> </p> <p>We identified four studies including 141 participants; two of these were in children (aged six months to 14.5 years) and two did not specify the age of the participants. Those taking part in the studies received different forms of vitamin E supplements (either water‐soluble or fat‐soluble), placebo (a substance containing no medication) or no supplements. Three studies stated that the treatment for each person was chosen at random, but one study only said the people were split into different groups. </p> <p><b>Key results</b> </p> <p><i>Water‐soluble vitamin E</i> </p> <p>Evidence from one study (45 participants) showed that supplementation may increase vitamin E levels in the blood after six months. Similar results were seen at the earlier time points of one month (two studies, 32 participants) and three three months (one study, 45 participants). Only one study (45 participants) reported weight at one and six months, but showed no difference between supplementation and placebo at either time point. </p> <p><i>Fat‐soluble vitamin E</i> </p> <p>Two studies (36 participants) reported higher levels of serum vitamin E after one month of fat‐soluble vitamin E supplements compared with no treatment, but a different study (36 participants) did not find any difference between supplementation and no treatment after three months. </p> <p>None of the studies in either comparison reported results for our planned outcomes of vitamin E total lipid ratio, the incidence of vitamin E‐specific deficiency disorders, lung function or quality of life. </p> <p>As the studies used different forms of supplements and different doses, it was difficult to combine the results and apply them to the wider cystic fibrosis population. The results showed that vitamin E supplementation may lead to an improvement in vitamin E levels in people with cystic fibrosis, but the quality of the evidence was low. </p> <p>Future studies should look at more specific outcomes such as vitamin E status, lung function and nutritional status, especially in people already receiving treatment with pancreatic enzymes and vitamin E supplements. They could also look at the best level of vitamin E supplements needed to be most clinically effective. </p> <p><b>Quality of the evidence</b> </p> <p>We judged the evidence to be low quality for the following reasons. We do not think that any of the people taking part in the studies could tell whether they received the supplements or the placebo, so that would not have affected the results; although they would have known if they were taking supplements or not taking anything. We could not tell from the information we have whether most of the studies were designed so all people had an equal chance of being in any of the groups. We also could not tell if anyone would have been able to guess in advance which group they would be in. It was also not clear if there were results reported for everyone taking part in the studies and the reasons why anyone might have dropped out of the studies. We do not know if these facts will affect our confidence in the results. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009422-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009422-sec-0087"></div> <h3 class="title" id="CD009422-sec-0088">Implications for practice</h3> <section id="CD009422-sec-0088"> <p>People with cystic fibrosis (CF) with pancreatic insufficiency have impaired absorption of fats which forms the clinical basis to supplement fat‐soluble vitamins including vitamin E. Three of the four studies in our review demonstrate that supplementation of vitamin E in people with CF leads to an improvement in vitamin E levels (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>), but in none of these studies was the status of pancreatic sufficiency or insufficiency in participants clear. Although none of the studies reported any detrimental effects of low vitamin E, the consequences of low vitamin E are well‐known and a deficient state is best avoided. None of the included studies reported other outcomes of interest (except a non‐statistically significant change in weight in one study (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>), so it is difficult to draw any recommendations for treatment from vitamin E supplementation in people with CF. It may be prudent to extrapolate that clinical vitamin E deficiency would be detrimental to the health of people with CF and our review findings do not challenge the established practice of supplementation to avoid deficiency. </p> </section> <h3 class="title" id="CD009422-sec-0089">Implications for research</h3> <section id="CD009422-sec-0089"> <p>It will be unethical to perform a study where vitamin E levels are not corrected (in the placebo group) to the point of clinical deficiency; however, studies looking at clinical or quality of life improvements with vitamin E supplementation are needed. Due to the heterogeneity of CF and the multiple concurrent therapies which people with CF are usually prescribed, it may be difficult to ascertain the extent of improvement related to vitamin E alone. </p> <p>Despite these challenges, larger research studies are needed in people with CF who are pancreatic insufficient and who are being treated with enteric‐coated pancreatic enzymes and supplemented with vitamin E (usually fat‐soluble preparations, e.g. as in the UK). These studies should look at more specific outcome measures such as vitamin E status (as most participants will already be receiving supplements), lung function, nutritional status and perhaps the reduction in airway inflammation. It may be useful to consider developing a core set of outcomes for research in this area. It is, however, beyond the mandate of this review to recommend clinical doses of vitamin E for CF therapy. However, future studies may decide to test or confirm the optimal dose of vitamin E required to achieve maximal clinical effectiveness. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009422-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009422-sec-0008"></div> <div class="table" id="CD009422-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: water‐soluble vitamin E compared with control for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Water‐soluble vitamin E compared with control for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children and adults with cystic fibrosis </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: 10 mg/kg/day of oral vitamin E tocopherol (d‐l alpha‐tocopheryl acetate) in water‐miscible solution </p> <p><b>Comparison</b>: no supplementation (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>) or placebo (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No supplementation or placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Water‐soluble oral vitamin E</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E total lipid ratio</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E levels in serum:</p> <p>umol/L</p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum level of vitamin E in the control group was 4.6 umol/L.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum level of vitamin E in the intervention group was 19.74 umol/L higher (13.48 umol/L higher to 26.00 umol/L higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 19.74 (13.48 to 26.00).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 study reported this outcome at the 6‐month time point ( <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a> ). </p> <p>2 further studies reported serum levels of vitamin E at 1 month and found a statistically significant result in favour of the supplemental group, MD 17.66 (95% CI 10.59 to 24.74) (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuropathy due to vitamin E deficiency</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retinopathy due to vitamin E deficiency</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Height</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub> % predicted: change from baseline </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BMI</b> : body mass index; <b>CI</b> : confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>MD</b>: mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded once becasue of indirectness in the data. The single study reporting at 6 months included only children and therefore the effect on adults is unknown. </p> <p>b. Downgaded once due to imprecision resulting from small numbers of participants (n = 45). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009422-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: fat‐soluble vitamin E compared with control for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fat‐soluble vitamin E compared with control for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children and adults with cystic fibrosis </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: fat‐soluble vitamin E 10 mg/kg/day in 2 trials (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>); participants &lt; 20 kg = 600 IU/Day &lt; 20 kg; participants &gt; 20 kg = 1200 IU/day in 1 trial (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>) </p> <p><b>Comparison</b>: no supplementation (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>) or placebo (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No supplementation or placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Fat‐soluble oral vitamin E</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E total lipid ratio</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured post‐intervention.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E levels in serum:</p> <p>umol/l</p> <p>Follow‐up: six months</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the trials measured this outcome at the 6‐month time point.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies reported serum levels of vitamin E at 1 month and found a statistically significant result in favour of the supplemental group, MD 13.59 (95% CI 9.52 to 17.66) (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). </p> <p>1 study reported serum levels of vitamin E at 3 months and found no statistically significant difference between intervention and control, MD 6.40 (95% CI ‐1.45 to 14.25) (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuropathy due to vitamin E deficiency</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retinopathy due to vitamin E deficiency</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Height</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub> % predicted: change from baseline </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BMI</b> : body mass index; <b>CI</b> : confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>MD</b>: mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009422-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009422-sec-0009"></div> <section id="CD009422-sec-0010"> <h3 class="title" id="CD009422-sec-0010">Description of the condition</h3> <p>Cystic fibrosis (CF) is caused by a genetic defect in the CF transmembrane conductance regulator (CFTR) protein in exocrine glands (e.g. the pancreas, airways, lungs, liver, salivary glands, reproductive tract and sweat glands) (<a href="./references#CD009422-bbs2-0029" title="GossCH , RosenfeldM . Update on cystic fibrosis epidemiology. Current Opinion in Pulmonary Medicine2004;10(6):510-4.">Goss 2004</a>; <a href="./references#CD009422-bbs2-0035" title="KeremE , ConwayS , ElbornS , HeijermanH . Standards of care for patients with cystic fibrosis: a European consensus. Journal of Cystic Fibrosis2005;4:7-26.">Kerem 2005</a>; <a href="./references#CD009422-bbs2-0050" title="WelshM , RamseyB , AccursoF , CuttingG . Cystic Fibrosis. In: ScriverCR , BeaudetAL , SlyWS , ValleD , editors(s). The Metabolic and Molecular Basis of Inherited Disease. 8th edition. New York: McGraw-Hill, 2001:5121-88.">Welsh 2001</a>). The disease is clinically characterized by thick, sticky secretions which impair numerous body systems, primarily the digestive and respiratory tracts. Within the respiratory system, CFTR dysfunction leads to a breakdown in mucociliary clearance, mucous retention, infection and inflammation. These in turn result in respiratory signs and symptoms including cough, copious production of sputum, difficulty in breathing, decreased lung function and respiratory tract infections most importantly due to <i>Pseudomonas aeruginosa</i> (<a href="./references#CD009422-bbs2-0017" title="AaronSD , RamotarK , FerrisW , VandemheenK , SaginurR , TullisE , et al. Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa . American Journal of Respiratory and Critical Care Medicine2004;169:811-5.">Aaron 2004</a>; <a href="./references#CD009422-bbs2-0037" title="KozlowskaWJ , BushA , WadeA , AuroraP , CarrSB , CastleRA , et al. Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2008;178(1):42-9.">Kozlowska 2008</a>; <a href="./references#CD009422-bbs2-0038" title="LinnaneBM , HallGL , NolanG , BrennanS , StickSM , SlyPD , et al. Lung function in infants with cystic fibrosis diagnosed by newborn screening. American Journal of Respiratory and Critical Care Medicine2008;178(12):1238-44.">Linnane 2008</a>)<i>.</i> Within the digestive system, pancreatic secretions are reduced with low volumes of fluid and bicarbonate in people with CF. This causes duct obstruction and retention and activation of secreted proenzymes in pancreatic ducts leading to destruction and fibrosis of the pancreas itself. This process begins in utero and continues after birth, leading to exocrine pancreatic insufficiency. Pancreatic insufficiency (decreased pancreatic enzyme release), failure of CFTR‐mediated intestinal bicarbonate secretion, deranged bile acid function and inactivation of enzymes by hyperacidity in the upper intestine all contribute to malabsorption (<a href="./references#CD009422-bbs2-0046" title="TaylorC , ConnollyS . Gastrointestinal disease and nutrition. In: HorsleyA , CunninghamS , InnesJA , editors(s). Cystic Fibrosis. Oxford: Oxford University Press, 2010:81-93.">Taylor 2010</a>). </p> <p>Approximately 85% to 90% of people with CF are pancreatic insufficient and have impaired fat absorption. These individuals are also prone to malabsorption of the fat soluble vitamins A, D, E and K and require pancreatic enzyme replacement therapy (PERT). Low vitamin E levels in people with CF put them at an increased risk of the detrimental effects of vitamin E deficiency. Vitamin E deficiency disorders are rare (<a href="./references#CD009422-bbs2-0025" title="DodgeJA , TurckD . Cystic fibrosis: nutritional consequences and management. Best Practice &amp; Research. Clinical Gastroenterology2006;20(3):531-46.">Dodge 2006</a>; <a href="./references#CD009422-bbs2-0043" title="SinaasappelM , SternM , LittlewoodJ , WolfeS , SteinkampdG , HeijermanHG , et al. Nutrition in patients with cystic fibrosis: a European Consensus. Journal of Cystic Fibrosis2002;1(2):51-75. [PMID: 15463811]">Sinaasappel 2002</a>; <a href="./references#CD009422-bbs2-0050" title="WelshM , RamseyB , AccursoF , CuttingG . Cystic Fibrosis. In: ScriverCR , BeaudetAL , SlyWS , ValleD , editors(s). The Metabolic and Molecular Basis of Inherited Disease. 8th edition. New York: McGraw-Hill, 2001:5121-88.">Welsh 2001</a>). They include, but are not limited to, cerebellar ataxia, peripheral neuropathy, myopathy, pigmented retinopathy and visual field contrition with loss of vision (<a href="./references#CD009422-bbs2-0048" title="UedaN , SuzukiY , RinoY , Takahashi T, ImadaT , TakanashiY , et al. Correlation between neurological dysfunction with vitamin E deficiency and gastrectomy. Journal of the Neurological Sciences2009;287:216-20. [DOI: 10.1016/j.jns.2009.07.020]">Ueda 2009</a>). Sensory motor neuropathy, which manifests as loss of reflexes and generalized weakness, may occur late in the course of vitamin E deficiency (<a href="./references#CD009422-bbs2-0044" title="SuskindDL . Nutritional Deficiencies During Normal Growth. Pediatric Clinics of North America2009;56(5):1035-53.">Suskind 2009</a>). Vitamin E deficiency can also manifest as cognitive impairment (<a href="./references#CD009422-bbs2-0036" title="KoscikRL , LaiHJ , LaxovaA , ZarembaKM , KosorokMR , DouglasJA , et al. Preventing early, prolonged vitamin E deficiency: an opportunity for better cognitive outcomes via early diagnosis through neonatal screening. Journal of Pediatrics2005;147(3 Suppl):S51-S56.">Koscik 2005</a>) and haemolytic anemias (<a href="./references#CD009422-bbs2-0045" title="SwannIL , KendraJR . Anaemia, vitamin E deficiency and failure to thrive in an infant. Clinical and Laboratory Haematology1998;20(1):61-3.">Swann 1998</a>; <a href="./references#CD009422-bbs2-0051" title="WilfondBS , FarrellPM , LaxovaA , MischlerE . Severe hemolytic anemia associated with vitamin E deficiency in infants with cystic fibrosis. Implications for neonatal screening. Clinica Pediatrica1994;33(1):2-7.">Wilfond 1994</a>). </p> <p>Current guidelines on the treatment of CF support PERT in individuals with pancreatic enzyme insufficiency, including fat‐soluble vitamin supplementation, which includes vitamin E (<a href="./references#CD009422-bbs2-0025" title="DodgeJA , TurckD . Cystic fibrosis: nutritional consequences and management. Best Practice &amp; Research. Clinical Gastroenterology2006;20(3):531-46.">Dodge 2006</a>; <a href="./references#CD009422-bbs2-0043" title="SinaasappelM , SternM , LittlewoodJ , WolfeS , SteinkampdG , HeijermanHG , et al. Nutrition in patients with cystic fibrosis: a European Consensus. Journal of Cystic Fibrosis2002;1(2):51-75. [PMID: 15463811]">Sinaasappel 2002</a>). Recommendations include a dosage of 100 IU to 400 IU per day for all individuals with CF (<a href="./references#CD009422-bbs2-0043" title="SinaasappelM , SternM , LittlewoodJ , WolfeS , SteinkampdG , HeijermanHG , et al. Nutrition in patients with cystic fibrosis: a European Consensus. Journal of Cystic Fibrosis2002;1(2):51-75. [PMID: 15463811]">Sinaasappel 2002</a>). </p> </section> <section id="CD009422-sec-0011"> <h3 class="title" id="CD009422-sec-0011">Description of the intervention</h3> <p>Vitamin E is a generic term for a group of eight fat‐soluble compounds, the tocopherols and tocotrienols, of which α‐tocopherol has the highest biological activity (<a href="./references#CD009422-bbs2-0044" title="SuskindDL . Nutritional Deficiencies During Normal Growth. Pediatric Clinics of North America2009;56(5):1035-53.">Suskind 2009</a>). It functions as an antioxidant that protects cell membranes from oxidative damage (<a href="./references#CD009422-bbs2-0040" title="PetersSA , KellyFJ . Vitamin E supplementation in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition1996;22:341-5.">Peters 1996</a>); its deficiency may worsen the burden of oxidative stress that results from constant inflammation, especially in respiratory and digestive systems which occurs in CF (<a href="./references#CD009422-bbs2-0022" title="Brigelius-FlohéR . Vitamin E: The Shrew Waiting to be Tamed. Free Radical Biology &amp; Medicine2009;46:543–54.">Brigelius‐Flohé 2009</a>). In addition to its antioxidant properties, vitamin E also helps improve nerve conduction (<a href="./references#CD009422-bbs2-0024" title="CynamonHA , MilovDE , ValensteinE , WagnerM . Effects of vitamin E deficiency on neurologic function in patients with cystic fibrosis. Pediatrics1988;113:637-9.">Cynamon 1988</a>), maintain the structural integrity of the haemoglobin membrane (<a href="./references#CD009422-bbs2-0045" title="SwannIL , KendraJR . Anaemia, vitamin E deficiency and failure to thrive in an infant. Clinical and Laboratory Haematology1998;20(1):61-3.">Swann 1998</a>) and, along with vitamin A, plays a role in vision (<a href="./references#CD009422-bbs2-0021" title="BinesJE , TrubyHD , ArmstrongDS , CarzinoR , GrimwoodR . Vitamin A and E deficiency and lung disease in infants with cystic fibrosis. Journal of Paediatrics and Child Health2005;41:663-8.">Bines 2005</a>). The specific mechanism of action for most of its effects is still relatively unknown (<a href="./references#CD009422-bbs2-0022" title="Brigelius-FlohéR . Vitamin E: The Shrew Waiting to be Tamed. Free Radical Biology &amp; Medicine2009;46:543–54.">Brigelius‐Flohé 2009</a>). </p> <p>Normal vitamin E blood levels generally range from about 23 μmol/L to 46 μmol/L. Plasma levels of 80 μmol/L and above are considered excessive (<a href="./references#CD009422-bbs2-0020" title="BiesalskiHK . Vitamin E requirements in parenteral nutrition. Gastroenterology2009;137(5):S92-S104. [DOI: 10.1053/j.gastro.2009.07.073]">Biesalski 2009</a>). However, vitamin E circulates in the blood bound to lipoproteins and, as a consequence, more accurate assessment of status should be assessed using the vitamin E to total lipid ratio, which has a sensitivity of 95% and a specificity of 99% for detecting vitamin E deficiency (<a href="./references#CD009422-bbs2-0047" title="ThurnhamDI , DaviesJA , CrumpBJ , SitunayakeRD , DavisM . The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. Annals of Clinical Biochemistry1986;23(Pt 5):514-20.">Thurnham 1986</a>). Normal ratios of α‐tocopherol to total lipid are greater than 0.6 mg and greater than 0.8 mg α‐tocopherol per gram total lipid in children and adults respectively. In a study in a non‐CF population, 47% of low vitamin E levels were normal and 58% with elevated plasma vitamin E were normal or low when re‐evaluated using vitamin E to total lipid ratio (<a href="./references#CD009422-bbs2-0052" title="WinbauerAN , PingreeSS , NuttallKL . Evaluating serum alpha-tocopherol (vitamin E) in terms of a lipid ratio. Annals Clinical and Laboratory Science1999;29(3):185-91.">Winbauer 1999</a>). </p> <p>Oral and parenteral multivitamin and vitamin E supplements have previously been used to ameliorate vitamin E deficiencies (<a href="./references#CD009422-bbs2-0018" title="AparicioJM , Belanger-QuintanaA , SuarezL . Ataxia with isolated vitamin E deficiency: case report and review of the literature. Journal of Pediatric Gastroenterology and Nutrition2001;33(2):206-10.">Aparicio 2001</a>; <a href="./references#CD009422-bbs2-0040" title="PetersSA , KellyFJ . Vitamin E supplementation in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition1996;22:341-5.">Peters 1996</a>; <a href="./references#CD009422-bbs2-0045" title="SwannIL , KendraJR . Anaemia, vitamin E deficiency and failure to thrive in an infant. Clinical and Laboratory Haematology1998;20(1):61-3.">Swann 1998</a>; <a href="./references#CD009422-bbs2-0048" title="UedaN , SuzukiY , RinoY , Takahashi T, ImadaT , TakanashiY , et al. Correlation between neurological dysfunction with vitamin E deficiency and gastrectomy. Journal of the Neurological Sciences2009;287:216-20. [DOI: 10.1016/j.jns.2009.07.020]">Ueda 2009</a>; <a href="./references#CD009422-bbs2-0014" title="Winklhofer RoobBM , van't HofMA , ShmerlingDH . Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations. American Journal of Clinical Nutrition1996;63(5):722-8. [CFGD REGISTER: GN48a] [MEDLINE: 96204950]">Winklhofer‐Roob 1996</a>). In CF, this supplementation is usually oral and used in conjunction with PERT. Oral vitamin E may be in the form of chewable or non‐chewable tablets, liquids or powders (<a href="./references#CD009422-bbs2-0039" title="Mayo Clinic. Vitamin E (oral route). www.mayoclinic.com/health/drug-information/DR601967/FLUSHCACHE=0&amp;UPDATEAPP=false (accessed 01 March 2011).">Mayo Clinic 2009</a>). Treatment is usually begun as soon as the serum vitamin E levels are investigated and is often life‐long. Even in large doses, treatment has few adverse effects (<a href="./references#CD009422-bbs2-0018" title="AparicioJM , Belanger-QuintanaA , SuarezL . Ataxia with isolated vitamin E deficiency: case report and review of the literature. Journal of Pediatric Gastroenterology and Nutrition2001;33(2):206-10.">Aparicio 2001</a>), which were therefore not specifically measured in this review. </p> </section> <section id="CD009422-sec-0012"> <h3 class="title" id="CD009422-sec-0012">How the intervention might work</h3> <p>Vitamin E supplementation aims to correct the deficiency of this vitamin in the body.</p> </section> <section id="CD009422-sec-0013"> <h3 class="title" id="CD009422-sec-0013">Why it is important to do this review</h3> <p>Routine fat‐soluble multivitamin supplementation has become the accepted standard of care in management of people with CF (<a href="./references#CD009422-bbs2-0019" title="BellSC , ShepherdRW . Optimising nutrition in cystic fibrosis. Journal of Cystic Fibrosis2002;1(2):47-50. [DOI: 10.1016/S1569-1993(02)00031-0]">Bell 2002</a>; <a href="./references#CD009422-bbs2-0021" title="BinesJE , TrubyHD , ArmstrongDS , CarzinoR , GrimwoodR . Vitamin A and E deficiency and lung disease in infants with cystic fibrosis. Journal of Paediatrics and Child Health2005;41:663-8.">Bines 2005</a>; <a href="./references#CD009422-bbs2-0043" title="SinaasappelM , SternM , LittlewoodJ , WolfeS , SteinkampdG , HeijermanHG , et al. Nutrition in patients with cystic fibrosis: a European Consensus. Journal of Cystic Fibrosis2002;1(2):51-75. [PMID: 15463811]">Sinaasappel 2002</a>). The general recommendation of the UK Cystic Fibrosis Trust Nutrition Working Group is regular estimation of serum vitamin E (in addition to lipid ratio) levels to guide vitamin E supplementation of up to 100 mg to 200 mg daily depending on the age of the individual (<a href="./references#CD009422-bbs2-0049" title="UK Cystic Fibrosis Trust Nutrition Working Group. Nutritional Management of Cystic Fibrosis. UK Cystic Fibrosis Trust, April 2002. [ISBN 0-9540536-5-6]">UK Cystic Fibrosis Trust 2002</a>). This is an updated version of a previous review (<a href="./references#CD009422-bbs2-0053" title="OkebukolaPO , KansraS , McCabeH . Vitamin E supplementation in people with cystic fibrosis. Cochrane Database of Systematic Reviews2011, Issue 11. Art. No: CD009422. [DOI: 10.1002/14651858.CD009422]">Okebukola 2011</a>; <a href="./references#CD009422-bbs2-0054" title="OkebukolaPO , KansraS , BarrettJ . Vitamin E supplementation in people with cystic fibrosis. Cochrane Database of Systematic Reviews2014, Issue 12. Art. No: CD009422. [DOI: 10.1002/14651858.CD009422.pub2]">Okebukola 2014</a>; <a href="./references#CD009422-bbs2-0055" title="OkebukolaPO , KansraS , BarrettJ . Vitamin E supplementation in people with cystic fibrosis. Cochrane Database of Systematic Reviews2017, Issue 3. Art. No: CD009422. [DOI: 10.1002/14651858.CD009422.pub3]">Okebukola 2017</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009422-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009422-sec-0014"></div> <p>To determine the effects of supplementation of vitamin E (whether this was over and above the usual supplements or the only vitamin E supplement given) on vitamin E deficiency or frequency of vitamin E deficiency disorders in people with CF. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009422-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009422-sec-0015"></div> <section id="CD009422-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009422-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials and quasi‐randomised controlled trials (including cluster‐randomised trials). </p> </section> <section id="CD009422-sec-0018"> <h4 class="title">Types of participants</h4> <p>All individuals with a diagnosis of CF who have not received a lung transplant. Diagnosis of CF should be based on a positive sweat test or genetic testing or both, plus one or more characteristic clinical features, a history of CF in a sibling, or a positive newborn screening test (<a href="./references#CD009422-bbs2-0027" title="FarrellPM , RosensteinBJ , WhiteTB , AccursoFJ , CastellaniC , CuttingGR , et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. Journal of Pediatrics2008;153(2):S4-S14.">Farrell 2008</a>). </p> <p>Vitamin E supplements are prescribed routinely only to people with CF who are pancreatic insufficient; people who are pancreatic sufficient are supplemented only when levels are found to be suboptimal from blood test results (usually in an antioxidant role). These are very different sets of individuals and vitamin E is supplemented for entirely different reasons. We therefore planned to analyse studies with people who were pancreatic insufficient separately from those studies with people who were pancreatic sufficient. </p> </section> <section id="CD009422-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Any preparation of vitamin E supplementation compared to placebo or no supplement, regardless of dosage or duration. This supplement could be over the usual amount of vitamin being given, or the only vitamin E supplement. </p> </section> <section id="CD009422-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD009422-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009422-list-0001"> <li> <p>Vitamin E total lipid ratio</p> </li> <li> <p>Vitamin E levels in serum</p> </li> <li> <p>Incidence of vitamin E‐specific deficiency disorders</p> <ol id="CD009422-list-0002"> <li> <p>peripheral neuropathy</p> </li> <li> <p>retinopathy</p> </li> <li> <p>myopathy and ataxia</p> </li> <li> <p>cognitive impairment</p> </li> <li> <p>haemolytic anemias</p> </li> </ol> </li> </ol> </p> </section> <section id="CD009422-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009422-list-0003"> <li> <p>Growth and nutritional status</p> <ol id="CD009422-list-0004"> <li> <p>weight</p> </li> <li> <p>height</p> </li> <li> <p>body mass index (BMI) percentile</p> </li> </ol> </li> <li> <p>Lung function tests</p> <ol id="CD009422-list-0005"> <li> <p>forced expiratory volume at one second (FEV<sub>1</sub>) (% predicted or L) </p> </li> <li> <p>forced vital capacity (FVC) (% predicted or L)</p> </li> </ol> </li> <li> <p>Quality of life (QoL) (using validated tools, e.g. the Cystic Fibrosis Questionnaire‐ Revised (CFQ‐R) (<a href="./references#CD009422-bbs2-0041" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>) and Cystic Fibrosis Quality of Life Questionnaire (CFQoL) (<a href="./references#CD009422-bbs2-0028" title="GeeL , AbbottJ , ConwayS , EtheringtonC , WebbA . Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax2000;55(11):946-54.">Gee 2000</a>)) </p> </li> </ol> </p> </section> </section> </section> <section id="CD009422-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>There are no restrictions regarding language or publication status.</p> <section id="CD009422-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We identified relevant studies from the Group's CF Trials Register using the term: vitamin E. </p> <p>The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the <i>Cochrane Library</i> ), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals ‐ <i>Pediatric Pulmonology</i> and the <i>Journal of Cystic Fibrosis</i>. Unpublished work is identified by searching the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the Cochrane Cystic Fibrosis and Genetic Disorders Group <a href="https://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of last search: 11 August 2020.</p> <p>We searched the online international trial registers (<a href="http://www.isrctn.org" target="_blank">ISRCTN</a> and <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) for any ongoing clinical trials; we planned to search the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) for the 2020 update; however, due to the Covid‐19 pandemic this resource was not available. The details of the search terms and resources are found in the appendices (<a href="./appendices#CD009422-sec-0093">Appendix 1</a>). </p> <p>Date of last search: 20 July 2020.</p> </section> <section id="CD009422-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We contacted manufacturers of vitamin E supplements for the results of studies that have been completed but not yet published, other ongoing or published studies. Where it was possible, we also contacted authors of included studies to obtain further information. </p> </section> </section> <section id="CD009422-sec-0026"> <h3 class="title" id="CD009422-sec-0026">Data collection and analysis</h3> <section id="CD009422-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two authors (PO and SK) independently reviewed titles and abstracts of all articles yielded from the literature search to identify potentially relevant studies. We assessed the full‐texts of these identified studies for inclusion using pre‐formulated screening criteria; and resolved disagreements by consensus. Due to a change in the author team between publication of the protocol and work commencing on the full review, only two authors selected studies instead of three as was indicated in the protocol. </p> </section> <section id="CD009422-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two authors (PO and SK) independently extracted pre‐determined variables into electronic data collection forms. As indicated above, due to a change in the author team, only two authors independently extracted data instead of three as was planned in the protocol. We resolved disagreements by discussion and reached a consensus. In addition to extracting data for all outcome variables, we also recorded the following data when available. </p> <section id="CD009422-sec-0029"> <h5 class="title">Study details</h5> <p> <ul id="CD009422-list-0006"> <li> <p>year of study</p> </li> <li> <p>study setting</p> </li> <li> <p>study design (cross‐over, cluster or parallel, single centre or multicentre)</p> </li> <li> <p>source of funding</p> </li> <li> <p>whether sample size was calculated</p> </li> <li> <p>sample size (number enrolled or randomised versus the number analysed)</p> </li> <li> <p>method of sequence generation</p> </li> <li> <p>method of allocation concealment</p> </li> <li> <p>who was blinded and for which outcomes</p> </li> </ul> </p> </section> <section id="CD009422-sec-0030"> <h5 class="title">Participant details</h5> <p> <ul id="CD009422-list-0007"> <li> <p>age of participants</p> </li> <li> <p>sex of participants</p> </li> <li> <p>severity of disease</p> </li> <li> <p>inclusion and exclusion criteria</p> </li> <li> <p>pancreatic sufficient versus pancreatic insufficient</p> </li> <li> <p>record of PERT</p> </li> <li> <p>pre‐ or post‐lung transplant</p> </li> <li> <p>presence or absence of diabetes mellitus</p> </li> <li> <p>numbers of dropouts and reasons for withdrawal from study (clinical, side effects, refusal, other) </p> </li> </ul> </p> </section> <section id="CD009422-sec-0031"> <h5 class="title">Intervention details</h5> <p> <ul id="CD009422-list-0008"> <li> <p>intervention formulation (i.e. capsule, solution, powder)</p> </li> <li> <p>dose of intervention</p> </li> <li> <p>frequency of administration</p> </li> <li> <p>duration of therapy</p> </li> <li> <p>concurrent medication(s)</p> </li> </ul> </p> <p>Where available, we planned to extract data relevant for outcomes at one month, up to three months, up to six months, up to 12 months and annually thereafter. However, we were only able to extract data at one month, up to three months, up to six months. We also converted the units from md/dL to umol/L which is the SI unit. </p> <p>We originally planned to present all formulations of vitamin E supplements combined, but have since decided it is more clinically appropriate to present the water‐soluble formulations separately from the fat‐soluble formulations. </p> <p>As stated above, vitamin E supplements are prescribed routinely only to people who are pancreatic insufficient; those who are pancreatic sufficient are supplemented only when levels are found to be suboptimal. We therefore planned to analyse studies with people who are pancreatic insufficient separately from studies with people who are pancreatic sufficient. However, as the included studies did not present sufficient information to allow us to do this, we have presented all data combined. </p> </section> </section> <section id="CD009422-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors independently judged the risk of bias of each included study, following the domain‐based evaluation as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009422-bbs2-0032" title="HigginsJPT , AltmanDG . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from cochrane-handbook.org.">Higgins 2011a</a>). We assessed the following domains as having a low, unclear or high risk of bias. </p> <p> <ol id="CD009422-list-0009"> <li> <p>Randomisation (low risk ‐ random number table, computer‐generated lists or similar methods; unclear risk ‐ described as randomised, but no details given; high risk ‐ e.g. alternation, the use of case record numbers, and dates of birth or day of the week) </p> </li> <li> <p>Concealment of allocation (low risk ‐ e.g. list from a central independent unit, on‐site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed opaque envelopes; unclear risk ‐ not described; high risk ‐ if allocation sequence was known to, or could be deciphered by the investigators who assigned participants or if the study was quasi‐randomised) </p> </li> <li> <p>Blinding (of participants, personnel and outcome assessors)</p> </li> <li> <p>Incomplete outcome data (whether investigators used an intention‐to‐treat analysis)</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other sources of bias</p> </li> </ol> </p> </section> <section id="CD009422-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>We reported the results from continuous outcomes as mean differences (MD) in change scores between groups and their 95% confidence intervals (CIs), as planned. Where only endpoint data were available, we planned to use the MD between endpoint scores, but no study reported endpoint data. All studies reported standard deviations (SD), which we used in the analysis. No studies reported standard errors (SEs). </p> <p>We had planned to report the results from dichotomous outcomes using odds ratios (OR) and 95% CIs. However, all the data were reported as continuous outcomes. We did not include adverse effects as an outcome of interest and no studies reported data on relevant adverse event outcomes. </p> <p>Initially, we had planned that where both change scores and endpoint data were available, we would combine both using the MD method in RevMan, being careful to use the appropriate SD (of both endpoint data and or change from baseline change) for each study.The differences were reported as MD in RevMan (<a href="./references#CD009422-bbs2-0042" title="Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.">RevMan 2011</a>). However, we did not combine change scores and endpoint data as standardised mean differences (SMDs). </p> <p>We planned to use the SMD and 95% CIs and calculate pooled effects, if studies reported outcomes using different measurement scales, but this was unnecessary as all the studies reported using the same measurement system. We did, however, convert all measurements to the SI unit (umol/L). </p> </section> <section id="CD009422-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>If we had found any cross‐over studies, we intended to calculate the mean treatment differences where possible and enter these using the fixed‐effect generic inverse variance (GIV) analysis in RevMan, to provide summary weighted differences and 95% CIs (<a href="./references#CD009422-bbs2-0042" title="Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.">RevMan 2011</a>). For any cross‐over studies we identify in future updates of this review, if we believe there is a carryover effect which will outlast any washout period included in the study or where second period data is unavailable, we will include only data from the first arm in the meta‐analysis (<a href="./references#CD009422-bbs2-0026" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>). Following peer review comments, we updated our planned methods and for multi‐arm studies, we now plan to include data from both arms, in line with the current guidance in the <i>Cochrane Handbook of Systematic Reviews</i> (<a href="./references#CD009422-bbs2-0033" title="HigginsJPT , DeeksJJ , Altman DG on behalf of the Cochrane Statistical Methods Group, editor(s). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from cochrane-handbook.org.">Higgins 2011b</a>). </p> </section> <section id="CD009422-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We planned to make up to three attempts to contact corresponding authors for studies in which there are missing data. If this was not productive, we planned to impute the missing data (SDs, standard errors (SEs) or other parameters) with replacement values based on statistical analysis as recommended in <i>The Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009422-bbs2-0033" title="HigginsJPT , DeeksJJ , Altman DG on behalf of the Cochrane Statistical Methods Group, editor(s). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from cochrane-handbook.org.">Higgins 2011b</a>). We planned to treat these as if they were observed, under the assumption that these data are not missing at random. We contacted the authors of the Keljo study to obtain some of the missing data which were used in the abstract. The authors replied and sent us the complete unpublished study (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>). We also planned to conduct a sensitivity analysis to test the effects of imputing missing data, but did not need to do this as we obtained the missing data directly from the authors. </p> </section> <section id="CD009422-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>If we had been able to combine sufficient data from multiple studies, we intended to describe any heterogeneity between the study results and test this to see if it reached statistical significance using the Chi² test. We considered heterogeneity to be significant when the P value is less than 0.10. We also planned to use the I² statistic (<a href="./references#CD009422-bbs2-0031" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>), where heterogeneity is categorized such that a value around 30% to 60% may represent moderate heterogeneity, 50% to 90% may represent substantial heterogeneity and over 70% to 100% is considerable heterogeneity as described in the <i>Cochrane Handbook of Systematic Reviews</i> (<a href="./references#CD009422-bbs2-0034" title="DeeksJJ , HigginsJPT , Altman DG on behalf of the Cochrane Statistical Methods Group, editor(s). Chapter 9: Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from cochrane-handbook.org.">Higgins 2011c</a>) </p> </section> <section id="CD009422-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We intended to analyse included studies for selective reporting by comparing study protocols with final reports to identify outcomes measured but not reported. Where protocols were not available, we cross‐referenced the 'Methods' section of the study report with the 'Results' section to assess whether study authors comment on all the outcomes they say they measured. We did not identify clinically important outcomes that were omitted in the included studies. We also attempted to reduce publication bias by searching unpublished sources and grey literature in addition to published sources. </p> </section> <section id="CD009422-sec-0038"> <h4 class="title">Data synthesis</h4> <p>If possible, we planned to enter data into meta‐analyses, combining all dose regimens and include the 95% CI, estimated using a fixed‐effect model. We also planned to utilise the random‐effects model whenever we had identified moderate or substantial heterogeneity (I² greater than 50%). </p> </section> <section id="CD009422-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We intended to study the following subgroups to investigate any heterogeneity that we might have identified, but were not able to do so due to a lack of data: </p> <p> <ol id="CD009422-list-0010"> <li> <p>children (under 18 years) and adults (18 years of age and over);</p> </li> <li> <p>method of diagnosis of CF (screened versus non‐screened);</p> </li> <li> <p>presence versus absence of co‐morbid conditions like diabetes mellitus.</p> </li> </ol> </p> </section> <section id="CD009422-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>We also planned to use the following sensitivity analyses to assess the impact of the potentially important factors on the overall outcomes, but were not able to do so due to a lack of data: </p> <p> <ol id="CD009422-list-0011"> <li> <p>analysis using a random‐effects model;</p> </li> <li> <p>per protocol analysis;</p> </li> <li> <p>high versus low risk of bias for each domain assessed;</p> </li> <li> <p>analysis with or without imputed data.</p> </li> </ol> </p> </section> <section id="CD009422-sec-0041"> <h4 class="title">Summary of findings tables</h4> <p>In a post hoc change from protocol, the review authors have presented two summary of findings tables, one for water‐soluble vitamin E versus control and one for fat‐soluble vitamin E versus control (<a href="./full#CD009422-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD009422-tbl-0002">summary of findings Table 2</a>). </p> <p>We have reported the following outcomes in both tables at six months.</p> <p> <ol id="CD009422-list-0012"> <li> <p>Vitamin E total lipid ratio</p> </li> <li> <p>Vitamin E levels in serum</p> </li> <li> <p>Neuropathy due to vitamin E deficiency</p> </li> <li> <p>Retinopathy due to vitamin E deficiency</p> </li> <li> <p>BMI</p> </li> <li> <p>Height</p> </li> <li> <p>FEV<sub>1</sub> % predicted (change from baseline) </p> </li> </ol> </p> <p>We determined the quality of the evidence using the GRADE approach; and downgraded evidence in the presence of a high risk of bias in at least one study, indirectness of the evidence, unexplained heterogeneity or inconsistency, imprecision of results, high probability of publication bias. We downgraded evidence by one level if they considered the limitation to be serious and by two levels if very serious. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009422-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009422-sec-0042"></div> <section id="CD009422-sec-0043"> <h3 class="title">Description of studies</h3> <section id="CD009422-sec-0044"> <h4 class="title">Results of the search</h4> <p>We identified 14 references to 13 studies from the search of our databases outlined above. We identified two additional studies from searching other databases (the <a href="http://www.isrctn.org" target="_blank">ISRCTN</a> website and <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). As illustrated in the PRISMA diagram, 15 studies were included for screening (<a href="#CD009422-fig-0001">Figure 1</a>). Of the 15 studies, four were included and 11 were excluded; the reasons for their exclusion are discussed below. </p> <div class="figure" id="CD009422-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD009422-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/image_n/nCD009422-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>We contacted the manufacturers of vitamin E supplements; however, they responded that they did not have any information about any unpublished or ongoing studies. </p> </section> <section id="CD009422-sec-0045"> <h4 class="title">Included studies</h4> <p>Four studies (n = 141) were included (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>; <a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). Two of these were only available as abstracts, which limited the amount of detail available for the review (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>); however, we were able to obtain additional information from the authors of the Keljo study. The fourth study is a full paper, but has only been published as part of conference proceedings and not in a journal (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>). Two of these studies are from the 1960s when PERT would not have been widely available and the management strategies for CF quite different from present times. </p> <p>There were insufficient studies included to conduct subgroup analyses or sensitivity analyses. </p> </section> <section id="CD009422-sec-0046"> <h4 class="title">Trial characteristics</h4> <p>Three of the four studies were described as randomised (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>; <a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>) and the fourth study was a controlled clinical study with no reference to randomisation during allocation of participants to study arms (<a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). However, we assumed that the authors performed some form of randomisation. All studies were of parallel design; two consisted of two arms (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>) and two of three arms (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). All were single‐centre studies; two were conducted in the USA (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>), one was conducted in Canada (<a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>) and the fourth study was conducted in the UK (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>). Study duration ranged from between 10 and 14 days (<a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>) to six months (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). </p> </section> <section id="CD009422-sec-0047"> <h4 class="title">Participants</h4> <p>All studies were of similar size, the number of participants ranged from 22 (<a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>) to 49 (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). Two studies recruited children only (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>) and two studies did not specify if participants were children or adults or a mix of both (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). Both paediatric studies gave details on the age of their participants: range six months to 14.5 years (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>); and mean (SD) age of participants in the treatment group 113.1 (65.12) months and in the placebo group 113.5 (63.99) months (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). Only one study gave any details of the gender split of participants (26 males, 19 females) (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). Two studies reported that participants had dropped out (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>), but only one gave specific reasons for this (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). In the remaining two studies there seemed be drop outs from the study, but these were not clearly discussed (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). Disease status varied between studies; one study described participants as having been stabilized with a study‐specific disease severity score of 2.22 in the treatment group and 2.10 in the placebo group (where 1 is good condition and 5 is very severe illness) (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). A second study described participants as having mild pulmonary disease (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>). A third study recruited participants admitted to hospital for a pulmonary exacerbation (<a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>) and the remaining study did not comment on disease status (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>). None of the studies explicitly stated whether the participants were pancreatic sufficient or insufficient. </p> </section> <section id="CD009422-sec-0048"> <h4 class="title">Interventions</h4> <p>Two studies compared fat‐soluble and water‐miscible supplements of vitamin E to no supplementation; both these studies used the dose of 10 mg/kg/day for the supplements (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). The water‐miscible formulation Harries used contained the surface active agent cremaphor El and glycerine (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>). Wong used an oral water‐soluble vitamin E preparation (Aquasol E) (<a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). A further study compared the same dose of water‐miscible vitamin E supplement to placebo (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). The remaining study compared a vegetable oil placebo to RRR alpha‐tocopherol which was given to participants weighing less than 20 kg at a dose of 600 IU/day and to participants weighing more than 20 kg at a dose of 1200 IU/day (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>). </p> <p>Two studies stated that participants continued to receive pancreatic enzyme supplementation during the study (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). One study stated participants continued to receive their standard vitamin supplements ADEKs<sup>®</sup> (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>). </p> </section> <section id="CD009422-sec-0049"> <h4 class="title">Outcomes</h4> <p>Only the measurement of serum vitamin E levels was common to all four included studies (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). Other outcomes measured in the blood included peroxide red blood cell (RBC) haemolysis (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>), serum glutamic oxalacetic transaminase (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>), tumour necrosis factor (TNF) alpha and interleukin‐6 levels (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>) and alpha tocopherol to cholesterol ratio (<a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). In addition, Levin reported on weight gain, muscle strength and subjective improvement (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). </p> </section> <section id="CD009422-sec-0050"> <h4 class="title">Excluded studies</h4> <p>A total of 11 studies were excluded from this review. Eight studies were excluded as they compared various vitamin E formulations, but not to a placebo or no supplement arm, and therefore not meeting the selection criteria for the review (<a href="./references#CD009422-bbs2-0005" title="HomolaL , HolcikovaA , PokojovaE , TomandlJ , MalaM . Prospective randomized open label comparison of fat soluble and water soluble vitamin supplementation in children with CF. Journal of Cystic Fibrosis2017;16(Suppl 1):S141. [CFGD REGISTER: GN273a] ">Homola 2017</a>; <a href="./references#CD009422-bbs2-0006" title="JacqueminE , HermeziuB , KibleurY , FriteauI , MathieuD , Le CozF , et al. Bioavailability of oral vitamin E formulations in adult volunteers and children with chronic cholestasis or cystic fibrosis. Journal of Clinical Pharmacy and Therapeutics2009;34(5):515-22. [CFGD REGISTER: GN216] [MEDLINE: 96204950]">Jacquemin 2009</a>; <a href="./references#CD009422-bbs2-0008" title="MunckA , GiniesJL , HuetF , WizlaN , GerardinM , DarviotE , et al. A new water-soluble oral vitamin E formulation in cystic fibrosis (CF) children [abstract]. Journal of Cystic Fibrosis2010;9 Suppl 1:S91, Abstract no: 352. [CFGD REGISTER: GN219] [MEDLINE: 96204950]">Munck 2010</a>; <a href="./references#CD009422-bbs2-0009" title="NasrSZ , O'LearyMH , HillermeierC . Correction of vitamin E deficiency with fat-soluble versus water-miscible preparations of vitamin E in patients with cystic fibrosis. Journal of Pediatrics1993;122(5 Pt 1):810-2. [CFGD REGISTER: GN42] ">Nasr 1993</a>; <a href="./references#CD009422-bbs2-0010" title="PapasK , KalbfleischJ , MohonR . Bioavailability of a novel, water-soluble vitamin E formulation in malabsorbing patients. Digestive Diseases and Sciences2007;52(2):347-52. [CFGD REGISTER: GN114] [MEDLINE: 96204950]">Papas 2007</a>; <a href="./references#CD009422-bbs2-0013" title="Winklhofer-RoobBM , ShmerlingDH , SchimekMG . Response of vitamin E deficient patients with cystic fibrosis (CF) to oral RRR-alpha-tocopherol or all-rac-alpha-tocopheryl acetate [abstract]. Clinical Nutrition1992;11 Suppl:67. [CFGD REGISTER: GN48b] ">Winklhofer‐Roob 1992</a>; <a href="./references#CD009422-bbs2-0014" title="Winklhofer RoobBM , van't HofMA , ShmerlingDH . Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations. American Journal of Clinical Nutrition1996;63(5):722-8. [CFGD REGISTER: GN48a] [MEDLINE: 96204950]">Winklhofer‐Roob 1996</a>; <a href="./references#CD009422-bbs2-0015" title="WoodLG , FitzgeraldDA , LeeAK , GargML . Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function. American Journal of Clinical Nutrition2003;77(1):150-9. [CFGD REGISTER: GN98] ">Wood 2003</a>). A further study was excluded because it described the use of vitamin E with placebo compared to vitamin E with ursodeoxycholic acid in a single participant, therefore the only difference in treatment was ursodeoxycholic acid (<a href="./references#CD009422-bbs2-0012" title="ThomasPS , BellamyM , GeddesD . Malabsorption of vitamin E in cystic fibrosis improved after ursodeoxycholic acid [letter]. Lancet1995;346(8984):1230-1. [CFGD REGISTER: GN77] [MEDLINE: 96054866]">Thomas 1995</a>). One study was excluded because it was not randomised or quasi‐randomised (<a href="./references#CD009422-bbs2-0011" title="SagelSD , SontagMK , AnthonyMM , EmmettP , PapasKA . Safety and efficacy of an antioxidant-rich multivitamin supplement in cystic fibrosis. Journal of Cystic Fibrosis2011;10(1):31-6. [CLINCALTRIALS.GOV: NCT01018303] ">Sagel 2011</a>). In the final study, which is still ongoing, tocotrienol is being used as a genetic modifier in people with CF (<a href="./references#CD009422-bbs2-0007" title="NCT00889434. Efficacy and safety study of EGCG/Tocotrienol in 18 patients with splicing-mutation-mediated cystic fibrosis (CF). http://clinicaltrials.gov/show/NCT00889434 (accessed 10 March 2012). [CLINICALTRIALS.GOV: NCT00889434] ">Kerem 2009</a>). One of the arms of the study entails supplementation with tocotrienol followed by a washout period; however, this study was excluded because it is not a study of vitamin E supplementation compared to placebo or control. </p> </section> </section> <section id="CD009422-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>Two of the included studies were published as short abstracts, hence the information available about the design and robustness was limited (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). However, one of the authors provided additional information by sending us the unpublished manuscript which contained further details (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>). Clear information was available for the remaining two studies (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). </p> <section id="CD009422-sec-0052"> <h4 class="title">Allocation</h4> <p>In three of the included studies the risk of bias from sequence generation was unclear (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). Two of these were described as randomised, but gave no details of the randomisation process (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>); the third merely stated that participants were divided into one of three groups (<a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). In the final study, there was a clear description of the randomisation process using labelled cards being placed in sealed envelopes and then each child accepted into the study group was assigned an envelope; we judged this to have a low risk of bias for sequence generation (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). </p> <p>Three of the studies did not discuss concealment of allocation and are judged to have an unclear risk of bias (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>) the fourth study used sealed envelopes to conceal the allocation sequence and is judged to have a low risk of bias (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). </p> </section> <section id="CD009422-sec-0053"> <h4 class="title">Blinding</h4> <p>In two studies, vitamin E supplementation is compared to no supplementation, so these studies cannot be blinded (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). Since we are reporting on objective outcome measurements, the absence of blinding is unlikely to increase the risk of bias in these studies and we have judged them to have an low risk of bias. Another study was double‐blinded and used a vegetable oil placebo, we therefore judged it to have a low risk of performance and detection bias (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>). In the study by Levin, the participants and the testers are described as being blinded; serum tocopherol levels were also not known to the examiners (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). We felt overall that it had a low risk of bias. </p> </section> <section id="CD009422-sec-0054"> <h4 class="title">Incomplete outcome data</h4> <p>Two studies reported that participants had dropped out (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). Only one of these gave specific reasons for these withdrawals and the attrition is balanced among the two groups; hence we judged this study to have a low risk of bias (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). In the study by Harries, vitamin E levels at the end of one month of supplementation were not available for one participant in the fat‐soluble group and two in the water‐miscible supplementation group (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>). An intention‐to‐treat analysis was not used; however, these missing data are unlikely to have a clinically significant impact on the results and we therefore judged the study to have a low risk of bias (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>). </p> <p>In the study by Wong, the initial number of participants allocated to each group is not clear and hence it is difficult to judge the number of dropouts across each group (<a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). In view of this insufficient reporting we judged it have an unclear risk of bias due to incomplete outcome data (<a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). In the remaining study, there appeared to be dropouts, but these were not clearly discussed and we judged this study to also have an unclear risk of bias (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>). </p> </section> <section id="CD009422-sec-0055"> <h4 class="title">Selective reporting</h4> <p>No study protocol was available to inform the risk of reporting bias in any of the four studies (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). All studies report results for the outcomes stated in their 'Methods' sections. In the absence of a protocol and no apparent risk of bias, we judge the overall risk of bias to be unclear in three studies (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). The authors of the Keljo study sent us the full study article on request, but the full article did not elucidate the methods of randomisation and did not fully report the results of the control group, which gives it a high risk for bias (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>). </p> </section> <section id="CD009422-sec-0056"> <h4 class="title">Other potential sources of bias</h4> <p>There is no information on how the diagnosis of CF was reached in any of the included studies or whether participants were pancreatic sufficient or insufficient, which may introduce a potential risk of bias. We therefore conclude a unclear risk of other potential bias for all studies. However, in the earlier studies the participants would not have had their pancreatic insufficiency treated with effective pancreatic enzymes as enteric‐coated preparations were not available. Instead, they would have been treated with a low‐fat diet to control symptoms of fat malabsorption. In addition, the dosages used in the Keljo study are higher than current international recommendations of: age up to 12 months, 40 IU to 80 IU; age one to three years, 50 IU to 150 IU; age four to seven years, 150 IU to 300 IU; and age eight years to adult, 150 IU to 500 IU (<a href="./references#CD009422-bbs2-0043" title="SinaasappelM , SternM , LittlewoodJ , WolfeS , SteinkampdG , HeijermanHG , et al. Nutrition in patients with cystic fibrosis: a European Consensus. Journal of Cystic Fibrosis2002;1(2):51-75. [PMID: 15463811]">Sinaasappel 2002</a>). </p> </section> </section> <section id="CD009422-sec-0057"> <h3 class="title" id="CD009422-sec-0057">Effects of interventions</h3> <p>See: <a href="./full#CD009422-tbl-0001"><b>Summary of findings 1</b> Summary of findings: water‐soluble vitamin E compared with control for cystic fibrosis</a>; <a href="./full#CD009422-tbl-0002"><b>Summary of findings 2</b> Summary of findings: fat‐soluble vitamin E compared with control for cystic fibrosis</a> </p> <p>The effects of interventions are summarised in the summary of findings tables, the quality of the evidence has been graded for pre‐defined outcomes (see above) and definitions of these gradings provided (<a href="./full#CD009422-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD009422-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD009422-sec-0058"> <h4 class="title">Water‐soluble vitamin E versus control</h4> <p>Three studies (n = 101) reported on this comparison (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>; <a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). </p> <section id="CD009422-sec-0059"> <h5 class="title">Primary outcomes</h5> <section id="CD009422-sec-0060"> <h6 class="title">1. Vitamin E: total lipid ratio</h6> <p>None of the studies using this comparison reported on this outcome.</p> </section> <section id="CD009422-sec-0061"> <h6 class="title">2. Vitamin E levels in serum</h6> <p>Three studies of water‐soluble vitamin E preparations reported on this outcome (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>; <a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). Data are available from two studies (n = 32) at the one‐month time point (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>) and show a statistically significant result in favour of the supplemented group, MD 17.66 (95% CI 10.59 to 24.74) (<a href="./references#CD009422-fig-0002" title="">Analysis 1.1</a>). Levin (n = 45) reported statistically significant improvement in vitamin E levels at three months, MD 11.61 (95% CI 4.77 to 18.45) and six months, MD 19.74 (95% CI 13.48 to 26.00) (low‐quality evidence) (<a href="./references#CD009422-fig-0002" title="">Analysis 1.1</a>). </p> </section> <section id="CD009422-sec-0062"> <h6 class="title">3. Incidence of vitamin E‐specific deficiency disorders</h6> <p>None of the studies include reported peripheral neuropathy, retinopathy, myopathy and ataxia, or cognitive impairment in either the supplemented or the placebo group. The studies did not report on clinical occurrence of haemolytic anaemia in either group. </p> </section> </section> <section id="CD009422-sec-0063"> <h5 class="title">Secondary outcomes</h5> <section id="CD009422-sec-0064"> <h6 class="title">1. Growth and nutritional status</h6> <section id="CD009422-sec-0065"> <p><b>a. Weight</b></p> <p>Levin (n = 45) reported an increase in weight in both the placebo and supplemented arms from the baseline to the one‐month and six‐month mark. However, the improvement in weight, which although was higher in the placebo group, was not statistically significant between groups at one month, MD ‐2.80 kg (95% CI ‐8.98 to 3.38) or after six months, MD ‐3.60 kg (95% CI ‐13.36 to 6.16) (<a href="./references#CD009422-fig-0003" title="">Analysis 1.2</a>). </p> </section> <section id="CD009422-sec-0066"> <p><b>b. Height</b></p> <p>None of the included studies reported any changes in height as an outcome measure.</p> </section> <section id="CD009422-sec-0067"> <p><b>c. BMI percentile</b></p> <p>None of the studies reported BMI percentile as an outcome measure.</p> </section> </section> <section id="CD009422-sec-0068"> <h6 class="title">2. Lung function tests</h6> <p>None of the studies measured and reported lung function (FEV<sub>1</sub> or FVC, either as % predicted or L). </p> </section> <section id="CD009422-sec-0069"> <h6 class="title">3. QoL</h6> <p>None of the included studies reported on QoL.</p> </section> </section> </section> <section id="CD009422-sec-0070"> <h4 class="title">Fat‐soluble vitamin E versus control</h4> <p>Three studies (n = 101) reported on this comparison (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). </p> <section id="CD009422-sec-0071"> <h5 class="title">Primary outcomes</h5> <section id="CD009422-sec-0072"> <h6 class="title">1. Vitamin E: total lipid ratio</h6> <p>A single study measured alpha tocopherol to cholesterol ratio at baseline, but did not report post‐intervention levels (<a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). </p> </section> <section id="CD009422-sec-0073"> <h6 class="title">2. Vitamin E levels in serum</h6> <p>Three studies of fat‐soluble vitamin E preparations reported on this outcome (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). At up to one month data were combined for two studies (n = 36) and showed a statistically significant result in favour of supplementation, MD 13.59 (95% CI 9.52 to 17.66). Data were also available at up to three months for a single study (36 participants), but were not statistically significant, MD 6.40 (95% CI ‐1.45 to 14.25) (<a href="./references#CD009422-fig-0004" title="">Analysis 2.1</a>). </p> </section> <section id="CD009422-sec-0074"> <h6 class="title">3. Incidence of vitamin E‐specific deficiency disorders</h6> <p>None of the studies include reported peripheral neuropathy, retinopathy, myopathy and ataxia, or cognitive impairment in either the supplemented or the placebo group. The studies did not report on clinical occurrence of haemolytic anaemia in either group. </p> </section> </section> <section id="CD009422-sec-0075"> <h5 class="title">Secondary outcomes</h5> <section id="CD009422-sec-0076"> <h6 class="title">1. Growth and nutritional status</h6> <p>None of the included studies reported any changes in weight, height or BMI percentile as an outcome measure. </p> </section> <section id="CD009422-sec-0077"> <h6 class="title">2. Lung function tests</h6> <p>None of the studies measured and reported lung function (FEV<sub>1</sub> or FVC, either as % predicted or L). </p> </section> <section id="CD009422-sec-0078"> <h6 class="title">3. QoL</h6> <p>None of the included studies reported on QoL.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009422-sec-0079" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009422-sec-0079"></div> <p>People with CF who are pancreatic insufficient are at an increased risk of malabsorption of fat‐soluble vitamins. Vitamin E supplementation, usually in combination with PERT, is universally recommended for people with CF who are pancreatic insufficient. We attempted to evaluate the effect of vitamin E supplementation compared with placebo in improving vitamin E levels and rectifying this deficiency in people with CF. We also wanted to assess the effect of vitamin E supplementation on the avoidance of vitamin E deficiency, growth, nutrition and respiratory status in people with CF. </p> <p>A state of vitamin E deficiency, as characterised by low levels of the vitamin, has been shown to be associated with problems such as haemolysis and cognitive difficulties. Vitamin E supplementation may have additional beneficial effects as an antioxidant and possibly also an anti‐inflammatory role. It was not in the remit of this review to explore the latter role. </p> <section id="CD009422-sec-0080"> <h3 class="title" id="CD009422-sec-0080">Summary of main results</h3> <p>Four studies with a total of 141 participants were included in the review (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). All studies used different formulations and doses of vitamin E for various durations of treatment. There were three eligible trials comparing fat‐soluble vitamin supplementation to control (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>), two of these studies also used water‐miscible formulations (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). One further study compared a water‐miscible formulation to control (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). The duration of supplementation in the studies also differed from 10 days (<a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>) to six months (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). Vitamin E supplementation is usually undertaken in conjunction with PERT, as was case in at least three of the four included studies (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). </p> <section id="CD009422-sec-0081"> <h4 class="title">Fat‐soluble vitamin E supplementation</h4> <p>Two studies (n = 32) evaluating fat‐soluble supplementation indicated improvements in vitamin E levels in serum at one month (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>); a third study (n = 45) also found higher levels of serum vitamin E in the supplemented group at three and six months, but the evidence was low‐quality (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). Only one study (n = 45) assessed our secondary outcome of nutritional status and reported an increase in weight in both supplemented and no treatment groups at one and six months, but there was no difference between groups at either time point (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). </p> </section> <section id="CD009422-sec-0082"> <h4 class="title">Water‐miscible vitamin E supplementation</h4> <p>Three studies reporting the use of water‐soluble supplements (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). At one month, two studies (n = 36) showed higher levels of serum vitamin E in the supplemented group (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). At three months, a single study (n = 36) in which participants were receiving the usual vitamin E supplements did not find any difference between supplements or placebo in serum vitamin E levels (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>). It is, however, difficult to definitively draw the conclusion that additional supplementation (over the usual amount) does not lead to a statistically significant improvement since the dosage of vitamin E supplementation may impact the results. </p> <p>None of the studies in either comparison report the review's primary outcomes of vitamin E total lipid ratio or the incidence of vitamin E‐specific deficiency disorders; however, baseline (untreated) vitamin E levels were low in all participants in three of the four included studies and these continued to be so in the placebo or no supplementation groups (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). None of the included studies in either comparison looked at improvements in lung function or cognition following supplementation; and hence it is difficult to draw any conclusions about the effect of vitamin E on these parameters. It is also instructive that none of the studies reported on many of the review outcomes and none of them had a common set of outcomes. It may thus be necessary to consider developing a core set of outcomes for research in this area. </p> </section> </section> <section id="CD009422-sec-0083"> <h3 class="title" id="CD009422-sec-0083">Overall completeness and applicability of evidence</h3> <p>Vitamin E levels were the primary outcome measures in only two of the four included studies (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). One of these studies also reported the alpha tocopherol to cholesterol ratio at baseline, which is also a valid measure of vitamin E levels; however, this study did not report alpha tocopherol to cholesterol ratios post‐intervention (<a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). None of the studies detail the basis for diagnosis of CF or pancreatic insufficiency. Varying formulations of vitamin E supplementation were used in the studies; three used fat‐soluble formulations (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>) and three used water‐miscible formulations (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). Bioavailability of vitamin E formulations can be variable. Comparison between various formulations was not in the remit of our review; however, this can potentially impact the serum vitamin levels thereby impacting the generalizability of the data. It is also possible that duration of supplementation may be a limitation to overall applicability as the longest study only lasted six months. Some of the included studies were conducted more than 50 years ago, when PERT was not available. Since PERT helps in fat (and fat‐soluble vitamin) absorption, the routine use of PERT will affect vitamin E levels in clinical practice. </p> </section> <section id="CD009422-sec-0084"> <h3 class="title" id="CD009422-sec-0084">Quality of the evidence</h3> <p>Two of these studies were published as short abstracts only (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). Assessment of one of these was limited (<a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>), but the author of the second abstract provided us with additional data (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>). One study was available as a full paper, but only presented at a conference and not published in a peer‐reviewed journal (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>). In the remaining three papers, the methods of randomisation and blinding are detailed only in one paper (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>). In one paper there is no presentation of standard deviation (SD) of the effect in the control group introducing a risk of bias (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>). </p> <p>We were only able to assess limited evidence from each comparison (fat‐soluble supplementation versus control and water‐miscible supplementation versus control) using the GRADE criteria (<a href="./full#CD009422-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD009422-tbl-0002">summary of findings Table 2</a>). The limitations of the available data due to imprecision and inconsistency compromise the quality of the evidence base for the review. Furthermore, indirectness (the study assessed only included children so the effects on adults are unknown) restricts the applicability of the evidence. </p> </section> <section id="CD009422-sec-0085"> <h3 class="title" id="CD009422-sec-0085">Potential biases in the review process</h3> <p>The two authors individually appraised all the studies and the risk of any further biases, other than those detailed in risk of bias tables, is very unlikely. None of the authors have any conflicts of interest to declare. </p> </section> <section id="CD009422-sec-0086"> <h3 class="title" id="CD009422-sec-0086">Agreements and disagreements with other studies or reviews</h3> <p>Vitamin E deficiency in CF is reported to cause haemolytic anaemia (<a href="./references#CD009422-bbs2-0051" title="WilfondBS , FarrellPM , LaxovaA , MischlerE . Severe hemolytic anemia associated with vitamin E deficiency in infants with cystic fibrosis. Implications for neonatal screening. Clinica Pediatrica1994;33(1):2-7.">Wilfond 1994</a>). None of the participants in the included studies were reported to have this complication. The exact relationship between vitamin E and lung health in CF is unclear. One study reported that vitamin E status is associated with an increased rate of pulmonary exacerbations in CF (<a href="./references#CD009422-bbs2-0030" title="Hakim F,  KeremE ,  RivlinJ ,  BenturL ,  StankiewiczH ,  Bdolach-AbramT ,  et al. Vitamins A and E and pulmonary exacerbations in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2007;45(3):347-53.">Hakim 2007</a>). However, a second study did not find any evidence to implicate vitamin E deficiency in the development of lung disease or airway inflammation (<a href="./references#CD009422-bbs2-0021" title="BinesJE , TrubyHD , ArmstrongDS , CarzinoR , GrimwoodR . Vitamin A and E deficiency and lung disease in infants with cystic fibrosis. Journal of Paediatrics and Child Health2005;41:663-8.">Bines 2005</a>). None of the included studies reported lung function parameters for us to examine this relationship. </p> <p>A Cochrane Review examined the effect of antioxidant supplementation (including vitamin E) on lung function in people with CF (<a href="./references#CD009422-bbs2-0023" title="CiofuO , LykkesfeldtJ . Antioxidant supplementation for lung disease in cystic fibrosis. Cochrane Database of Systematic Reviews2019, Issue 10. Art. No: CD007020. [DOI: 10.1002/14651858.CD007020.pub4]">Ciofu 2019</a>). While this review concluded that it is difficult to assess the effect of antioxidants due to the very intensive antibiotic treatment and other concurrent treatments that people with CF take. There was limited evidence of some improvement in lung function with inhaled and oral glutathione and in nutritional status with oral glutathione, but no evidence of any positive treatment effect of antioxidants on quality of life, antibiotic days or adverse events. </p> <p>As part of the Wisconsin CF Neonatal Screening Project, Koscik reported low cognitive scores in people with CF who had low serum vitamin E levels at diagnosis (<a href="./references#CD009422-bbs2-0036" title="KoscikRL , LaiHJ , LaxovaA , ZarembaKM , KosorokMR , DouglasJA , et al. Preventing early, prolonged vitamin E deficiency: an opportunity for better cognitive outcomes via early diagnosis through neonatal screening. Journal of Pediatrics2005;147(3 Suppl):S51-S56.">Koscik 2005</a>). None of the studies included in the review report cognitive scores as an outcome measure. We are thus unable to draw any firm conclusion about the effect of vitamin E on cognitive function in CF. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009422-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/urn:x-wiley:14651858:media:CD009422:CD009422-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD009422-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/image_n/nCD009422-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/image_t/tCD009422-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/full#CD009422-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/image_n/nCD009422-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009422-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/urn:x-wiley:14651858:media:CD009422:CD009422-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Water‐miscible vitamin E supplementation versus control, Outcome 1: Serum vitamin E levels" data-id="CD009422-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/image_n/nCD009422-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/image_t/tCD009422-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Water‐miscible vitamin E supplementation versus control, Outcome 1: Serum vitamin E levels </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/references#CD009422-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/image_n/nCD009422-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009422-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/urn:x-wiley:14651858:media:CD009422:CD009422-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Water‐miscible vitamin E supplementation versus control, Outcome 2: Weight" data-id="CD009422-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/image_n/nCD009422-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/image_t/tCD009422-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Water‐miscible vitamin E supplementation versus control, Outcome 2: Weight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/references#CD009422-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/image_n/nCD009422-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009422-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/urn:x-wiley:14651858:media:CD009422:CD009422-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fat‐soluble vitamin E supplementation versus control, Outcome 1: Serum vitamin E levels" data-id="CD009422-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/image_n/nCD009422-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/image_t/tCD009422-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Fat‐soluble vitamin E supplementation versus control, Outcome 1: Serum vitamin E levels </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/references#CD009422-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/media/CDSR/CD009422/image_n/nCD009422-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009422-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: water‐soluble vitamin E compared with control for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Water‐soluble vitamin E compared with control for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children and adults with cystic fibrosis </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: 10 mg/kg/day of oral vitamin E tocopherol (d‐l alpha‐tocopheryl acetate) in water‐miscible solution </p> <p><b>Comparison</b>: no supplementation (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>) or placebo (<a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a>) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No supplementation or placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Water‐soluble oral vitamin E</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E total lipid ratio</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E levels in serum:</p> <p>umol/L</p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum level of vitamin E in the control group was 4.6 umol/L.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum level of vitamin E in the intervention group was 19.74 umol/L higher (13.48 umol/L higher to 26.00 umol/L higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 19.74 (13.48 to 26.00).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 study reported this outcome at the 6‐month time point ( <a href="./references#CD009422-bbs2-0003" title="LevinS , GordonMH , NitowskyHM , GoldmanC , di Sant'AgneseP , GordonHH . Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: 74154485]LevinS . Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: 74154485]">Levin 1961</a> ). </p> <p>2 further studies reported serum levels of vitamin E at 1 month and found a statistically significant result in favour of the supplemental group, MD 17.66 (95% CI 10.59 to 24.74) (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuropathy due to vitamin E deficiency</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retinopathy due to vitamin E deficiency</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Height</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub> % predicted: change from baseline </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BMI</b> : body mass index; <b>CI</b> : confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>MD</b>: mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded once becasue of indirectness in the data. The single study reporting at 6 months included only children and therefore the effect on adults is unknown. </p> <p>b. Downgaded once due to imprecision resulting from small numbers of participants (n = 45). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: water‐soluble vitamin E compared with control for cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/full#CD009422-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009422-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: fat‐soluble vitamin E compared with control for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fat‐soluble vitamin E compared with control for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children and adults with cystic fibrosis </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: fat‐soluble vitamin E 10 mg/kg/day in 2 trials (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>); participants &lt; 20 kg = 600 IU/Day &lt; 20 kg; participants &gt; 20 kg = 1200 IU/day in 1 trial (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>) </p> <p><b>Comparison</b>: no supplementation (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>) or placebo (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No supplementation or placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Fat‐soluble oral vitamin E</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E total lipid ratio</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured post‐intervention.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin E levels in serum:</p> <p>umol/l</p> <p>Follow‐up: six months</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the trials measured this outcome at the 6‐month time point.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies reported serum levels of vitamin E at 1 month and found a statistically significant result in favour of the supplemental group, MD 13.59 (95% CI 9.52 to 17.66) (<a href="./references#CD009422-bbs2-0001" title="HarriesJT , MullerDP . Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood1971;46(247):341-4. [CFGD REGISTER: GN49b] HarriesJT , MullerDPR . Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49] ">Harries 1969</a>; <a href="./references#CD009422-bbs2-0004" title="WongLTK , HalsteadC , DavidsonAGF , FangPM . Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology1988;5 Suppl 2:144. [CFGD REGISTER: GN52] ">Wong 1988</a>). </p> <p>1 study reported serum levels of vitamin E at 3 months and found no statistically significant difference between intervention and control, MD 6.40 (95% CI ‐1.45 to 14.25) (<a href="./references#CD009422-bbs2-0002" title="KelijoDJ , GiroirB , JialalI . Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b] KeljoDJ , GiroirB , JialalI . Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. [CFGD REGISTER: GN87] ">Keljo 2000</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neuropathy due to vitamin E deficiency</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retinopathy due to vitamin E deficiency</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Height</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub> % predicted: change from baseline </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BMI</b> : body mass index; <b>CI</b> : confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>MD</b>: mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: fat‐soluble vitamin E compared with control for cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/full#CD009422-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009422-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Water‐miscible vitamin E supplementation versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Serum vitamin E levels <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.66 [10.59, 24.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.61 [4.77, 18.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.74 [13.48, 26.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Water‐miscible vitamin E supplementation versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/references#CD009422-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009422-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Fat‐soluble vitamin E supplementation versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Serum vitamin E levels <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.59 [9.52, 17.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.40 [‐1.45, 14.25]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Fat‐soluble vitamin E supplementation versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009422.pub4/references#CD009422-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009422.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009422-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009422-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009422-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD009422-note-0008">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD009422-note-0006">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD009422-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD009422-note-0011">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD009422-note-0005">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009422-note-0003">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD009422-note-0004">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009422\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009422\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009422\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009422\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009422\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009422\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009422\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009422\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009422\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009422\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009422\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009422\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009422\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009422\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009422\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009422\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009422\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009422\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009422.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009422.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009422.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009422.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009422.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728553687"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009422.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728553690"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009422.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec74f8e10f431',t:'MTc0MDcyODU1NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 